PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30059366-0 2018 Dysregulation of bcl-2 enhanced rotenone-induced alpha-synuclein aggregation associated with autophagic pathways. Rotenone 32-40 synuclein alpha Rattus norvegicus 49-64 29181664-2 2017 In rats intranasally receiving rotenone in a dose of 2.5 mg/kg every other day over 2 weeks, a decrease in the density of dopaminergic neurons and the area of astrocyte processes in the olfactory bulbs, activation of microglia in the glomerular layer, and enhanced alpha-synuclein phosphorylation and its accumulation in the bodies of mitral layer neurons were observed. Rotenone 31-39 synuclein alpha Rattus norvegicus 265-280 29327204-7 2018 Besides, it significantly inhibited rotenone-induced decrease in TH expression and increase in alpha-synuclein immunoreactivity in the midbrains and striata of the rats. Rotenone 36-44 synuclein alpha Rattus norvegicus 95-110 29196028-6 2018 In contrast, overexpression of Srf attenuated the cells" sensitivity to rotenone and alleviated rotenone-induced alpha-synuclein accumulation. Rotenone 96-104 synuclein alpha Rattus norvegicus 113-128 29181664-3 2017 The observed changes agree with the hypothesis on pathological alpha-synuclein transport via the olfactory route in Parkinson"s disease and confirm relevance of the rotenone model of Parkinson"s disease for studies of the pathological accumulation of alpha-synuclein. Rotenone 165-173 synuclein alpha Rattus norvegicus 251-266 28132806-0 2017 Rifampicin pre-treatment inhibits the toxicity of rotenone-induced PC12 cells by enhancing sumoylation modification of alpha-synuclein. Rotenone 50-58 synuclein alpha Rattus norvegicus 119-134 28619113-9 2017 Rotenone-induced insoluble alpha-synuclein was also targeted by Ser129-phosphoryation to the proteasome pathway. Rotenone 0-8 synuclein alpha Rattus norvegicus 27-42 28132806-1 2017 Our previous research revealed that rifampicin could protect PC12 (pheochromocytoma 12) cells from rotenone-induced cytotoxicity by reversing the aggregation of alpha-synuclein. Rotenone 99-107 synuclein alpha Rattus norvegicus 161-176 28132806-12 2017 In conclusion, rifampicin might reduce the cytotoxicity of rotenone-induced PC12 cells by promoting SUMOylation of alpha-synuclein. Rotenone 59-67 synuclein alpha Rattus norvegicus 115-130 27473339-11 2016 Furthermore, OPTN colocalizes with LC3 (autophagic vesicle marker) and alpha-synuclein positive puncta in rotenone-treated animals, potentially indicating an important role in autophagy and PD pathogenesis. Rotenone 106-114 synuclein alpha Rattus norvegicus 71-86 27876560-5 2017 Rotenone caused a dose-dependent increase in alpha-synuclein in the substantia nigra. Rotenone 0-8 synuclein alpha Rattus norvegicus 45-60 27876560-11 2017 Together, our data indicate that daily subcutaneous injection of 2mg/kg rotenone in rats facilitates the formation of alpha-synuclein and reproduces the typical features of PD, while maintaining low mortality. Rotenone 72-80 synuclein alpha Rattus norvegicus 118-133 27585560-4 2017 In this context, the aim of this study was to assess the behavioural and neuropathological impact of exposing rats with a subclinical load of alpha-synuclein to subclinical doses of the organic pesticide, rotenone. Rotenone 205-213 synuclein alpha Rattus norvegicus 142-157 27585560-11 2017 These results indicate that exposing rats with a subclinical alpha-synuclein-induced pathology to the pesticide, rotenone, profoundly exacerbates their Parkinsonian neuropathology and dysfunction, and highlights the potential importance of this interaction in the etiology of, and in driving the pathogenesis of Parkinson"s disease. Rotenone 113-121 synuclein alpha Rattus norvegicus 61-76 28349030-8 2017 alpha-Synuclein expression in the nigrostriatum was enhanced by induction of rotenone-induced Parkinson disease, in contrast, treadmill exercise suppressed alpha-synuclein expression in the rotenone-induced Parkinson rats. Rotenone 77-85 synuclein alpha Rattus norvegicus 0-15 28349030-8 2017 alpha-Synuclein expression in the nigrostriatum was enhanced by induction of rotenone-induced Parkinson disease, in contrast, treadmill exercise suppressed alpha-synuclein expression in the rotenone-induced Parkinson rats. Rotenone 190-198 synuclein alpha Rattus norvegicus 156-171 27632381-5 2016 Further, acteoside inhibited rotenone-induced alpha-synuclein, caspase-3 upregulation and microtubule-associated protein 2 (MAP2) downregulation in PD rats. Rotenone 29-37 synuclein alpha Rattus norvegicus 46-61 26075822-2 2015 Occupational exposure to the mitochondrial complex I inhibitor rotenone increases PD risk; rotenone-exposed rats show systemic mitochondrial defects but develop specific neuropathology, including alpha-synuclein aggregation and degeneration of substantia nigra dopaminergic neurons. Rotenone 63-71 synuclein alpha Rattus norvegicus 196-211 27706423-5 2016 It was found that 2 mg/kg/day rotenone increased amyloid-beta peptide, hyperphosphorylation of TAU and alpha-synuclein. Rotenone 30-38 synuclein alpha Rattus norvegicus 103-118 26649942-6 2015 More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux. Rotenone 93-101 synuclein alpha Rattus norvegicus 56-60 26649942-6 2015 More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux. Rotenone 93-101 synuclein alpha Rattus norvegicus 61-76 26649942-6 2015 More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux. Rotenone 93-101 synuclein alpha Rattus norvegicus 163-167 26075822-2 2015 Occupational exposure to the mitochondrial complex I inhibitor rotenone increases PD risk; rotenone-exposed rats show systemic mitochondrial defects but develop specific neuropathology, including alpha-synuclein aggregation and degeneration of substantia nigra dopaminergic neurons. Rotenone 91-99 synuclein alpha Rattus norvegicus 196-211 26075822-5 2015 However, in rotenone-exposed rats, progressive motor deficits were substantially attenuated contralateral to alpha-synuclein knockdown. Rotenone 12-20 synuclein alpha Rattus norvegicus 109-124 26075822-6 2015 Correspondingly, rotenone-induced degeneration of nigral dopaminergic neurons, their dendrites, and their striatal terminals was decreased ipsilateral to alpha-synuclein knockdown. Rotenone 17-25 synuclein alpha Rattus norvegicus 154-169 26075822-7 2015 These data show that alpha-synuclein knockdown is neuroprotective in the rotenone model of PD and indicate that endogenous alpha-synuclein contributes to the specific vulnerability of dopaminergic neurons to systemic mitochondrial inhibition. Rotenone 73-81 synuclein alpha Rattus norvegicus 21-36 25433145-0 2015 The molecular mechanism of rotenone-induced alpha-synuclein aggregation: emphasizing the role of the calcium/GSK3beta pathway. Rotenone 27-35 synuclein alpha Rattus norvegicus 44-59 25433145-3 2015 Here, we assessed the aggregation of alpha-synuclein in PC12 cells with or without cross-linking following rotenone exposure via a variety of methods, including western blotting, immunofluorescence and electron microscopy. Rotenone 107-115 synuclein alpha Rattus norvegicus 37-52 25433145-4 2015 We demonstrated that rotenone increased the intracellular calcium levels and induced the aggregation and phosphorylation of alpha-synuclein in a calcium-dependent manner. Rotenone 21-29 synuclein alpha Rattus norvegicus 124-139 25433145-11 2015 These results suggest that rotenone-induced alpha-synuclein aggregation is mediated by the calcium/GSK3beta signaling pathway. Rotenone 27-35 synuclein alpha Rattus norvegicus 44-59 24946750-2 2015 Our recent studies have shown the beneficial effects of a heat shock protein (HSP) inducer, carbenoxolone (Cbx), in reducing the aggregation of alpha-synuclein in a rotenone-based rat model of PD. Rotenone 165-173 synuclein alpha Rattus norvegicus 144-159 23295396-0 2013 The behavioural and neuropathological impact of intranigral AAV-alpha-synuclein is exacerbated by systemic infusion of the Parkinson"s disease-associated pesticide, rotenone, in rats. Rotenone 165-173 synuclein alpha Rattus norvegicus 64-79 23567316-6 2013 Neonatal LPS exposure enhanced rotenone-stimulated accumulation of alpha-synuclein aggregation and increment in DAT protein expression in the cytoplasmic compartment of the SN, and in the synaptosomal compartment of the striatum of adult rats. Rotenone 31-39 synuclein alpha Rattus norvegicus 67-82 25446361-1 2015 BACKGROUND: Rotenone is an environmental neurotoxin that induces accumulation of alpha-synuclein and degeneration of dopaminergic neurons in substantia nigra pars compacta (SNpc), but the molecular mechanisms are not fully understood. Rotenone 12-20 synuclein alpha Rattus norvegicus 81-96 25446361-6 2015 In cultured PC12 cells, rotenone also induced increases in protein levels of alpha-synuclein, microtubule-associated protein 1 light chain 3-II, Beclin 1, and p62. Rotenone 24-32 synuclein alpha Rattus norvegicus 77-92 24833599-8 2014 Furthermore, overexpression of E46K mutant alpha-synuclein increased the vulnerability of differentiated PC12 cells to rotenone treatment, which would be partly due to its inhibitory effects on autophagy. Rotenone 119-127 synuclein alpha Rattus norvegicus 43-58 24002177-4 2013 The results showed that rotenone led to a decrease in expression of 14-3-3 protein and mRNA, and an increase in expression and aggregation of alpha-synuclein protein. Rotenone 24-32 synuclein alpha Rattus norvegicus 142-157 23567316-0 2013 Neonatal exposure to lipopolysaccharide enhances accumulation of alpha-synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life. Rotenone 177-185 synuclein alpha Rattus norvegicus 65-80 23295396-7 2013 We found that exposing AAV-alpha-synuclein-treated rats to rotenone led to a model in which the classical Parkinson"s disease triad of progressive motor dysfunction, nigrostriatal neurodegeneration and alpha-synucleinopathy was evident. Rotenone 59-67 synuclein alpha Rattus norvegicus 27-42 23128054-0 2013 Deletion in exon 5 of the SNCA gene and exposure to rotenone leads to oligomerization of alpha-synuclein and toxicity to PC12 cells. Rotenone 52-60 synuclein alpha Rattus norvegicus 26-30 23128054-0 2013 Deletion in exon 5 of the SNCA gene and exposure to rotenone leads to oligomerization of alpha-synuclein and toxicity to PC12 cells. Rotenone 52-60 synuclein alpha Rattus norvegicus 89-104 23128054-5 2013 When exposed to rotenone, these cell lines which over expressed exon 5-lacking form of alpha-syn isoforms showed the formation of oligomeric species and toxicity to PC12 cells. Rotenone 16-24 synuclein alpha Rattus norvegicus 87-96 23229893-12 2013 Association of SUMO-1 with lysosomes was also detected in glial cells bearing alpha-synuclein aggregates in a rotenone-lesioned rat model. Rotenone 110-118 synuclein alpha Rattus norvegicus 78-93 19626387-7 2010 The PD-marker protein alpha-synuclein decreased, in its native form, in substantia nigra and striatum of rotenone-treated rats, while monoubiquitinated alpha-synuclein increased in the same regions. Rotenone 105-113 synuclein alpha Rattus norvegicus 22-37 21067569-4 2010 Rotenone at 0.5 nM was able to induce alpha-synuclein and beta amyloid aggregation, as well as increased hyperphosphorylation of tau, although high concentrations of this pesticide (over 1 nM) lead cells to death before protein aggregation. Rotenone 0-8 synuclein alpha Rattus norvegicus 38-53 22198020-3 2012 Thus, in order to develop a more relevant model, we sought to determine if administration of the Parkinson"s disease-associated pesticide, rotenone, into the substantia nigra of rats overexpressing the Parkinson"s disease-associated protein, alpha-synuclein, could reliably model the triad of classic features of the human disease. Rotenone 139-147 synuclein alpha Rattus norvegicus 242-257 22490660-10 2012 Under confocal microscopy, the aggregates of alpha-synuclein protein in PC12 cells were detected more in Ad-null group and rotenone group than that in Ad/14-3-3 gamma group. Rotenone 123-131 synuclein alpha Rattus norvegicus 45-60 19626387-9 2010 Furthermore, monoubiquitinated alpha-synuclein increased its localization in nuclei isolated from substantia nigra of rotenone-treated rats, an effect also prevented by VPA treatment. Rotenone 118-126 synuclein alpha Rattus norvegicus 31-46 19924288-5 2009 The rotenone infusion also reduced the DA content, the glutathione and superoxide dismutase activities, and induced alpha-synuclein expression, when compared to the contralateral side. Rotenone 4-12 synuclein alpha Rattus norvegicus 116-131 17273802-7 2007 In the substantia nigra of rotenone-treated rats, four of six had reduced numbers of tyrosine hydroxylase-positive neurons and all six had increased nigral alpha-synuclein expression. Rotenone 27-35 synuclein alpha Rattus norvegicus 156-171 19595768-7 2009 Rotenone treatment caused an acute reduction in alpha-synuclein-immunoreactivity, but this was followed 6 months later by a robust increase in aggregate pathology and cytoplasmic inclusions that were similar in appearance to enteric Lewy-bodies in idiopathic PD. Rotenone 0-8 synuclein alpha Rattus norvegicus 48-63 18289173-5 2008 Rotenone subcutaneously infused for 14 days induced PD symptoms in rats, as indicated by reduced spontaneous locomotor activity (hypokinesis), loss of tyrosine hydroxylase (TH, a marker enzyme for dopamine neurons) immunoreactivity in the substantia nigra and striatum, obvious alpha-synuclein accumulation, downregulated DAT protein expression, and upregulated D2R expression. Rotenone 0-8 synuclein alpha Rattus norvegicus 278-293 17690729-0 2006 alpha-Synuclein redistributed and aggregated in rotenone-induced Parkinson"s disease rats. Rotenone 48-56 synuclein alpha Rattus norvegicus 0-15 17690729-1 2006 Objective To observe the influence of rotenone on the distribution of alpha-synuclein (ASN) in rat model of Parkinson"s disease (PD). Rotenone 38-46 synuclein alpha Rattus norvegicus 70-85 17690729-1 2006 Objective To observe the influence of rotenone on the distribution of alpha-synuclein (ASN) in rat model of Parkinson"s disease (PD). Rotenone 38-46 synuclein alpha Rattus norvegicus 87-90 17690729-8 2006 In rotenone treated rats, ASN positive cells increased in global brain but not distributed in an even manner. Rotenone 3-11 synuclein alpha Rattus norvegicus 26-29 17690729-10 2006 Conclusion In rotenone administrated PD rats, ASN protein aggregated in several brain regions but most obviously in striatum and substantia nigra, and the distribution region of ASN was changed from peri-synapse to the cytoplasm and nucleus of dopaminergic neuron. Rotenone 14-22 synuclein alpha Rattus norvegicus 46-49 17690729-10 2006 Conclusion In rotenone administrated PD rats, ASN protein aggregated in several brain regions but most obviously in striatum and substantia nigra, and the distribution region of ASN was changed from peri-synapse to the cytoplasm and nucleus of dopaminergic neuron. Rotenone 14-22 synuclein alpha Rattus norvegicus 178-181 15790535-19 2005 Greenamyre, Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation, Exp. Rotenone 25-33 synuclein alpha Rattus norvegicus 97-112 15084427-1 2004 Rotenone (an inhibitor of mitochondrial complex I) has been proposed as a model of Parkinson"s disease (PD) as it induces nigrostriatal degeneration associated with alpha-synuclein inclusions. Rotenone 0-8 synuclein alpha Rattus norvegicus 165-180 15265640-1 2004 Peripherally and locally administered rotenone (an inhibitor of mitochondrial complex I) has been proposed as a model of Parkinson"s disease (PD) as it induces nigrostriatal degeneration associated with alpha-synuclein inclusions. Rotenone 38-46 synuclein alpha Rattus norvegicus 203-218 15280438-1 2004 Chronic complex I inhibition caused by rotenone induces features of Parkinson"s disease in rats, including selective nigrostriatal dopaminergic degeneration and Lewy bodies with alpha-synuclein-positive inclusions. Rotenone 39-47 synuclein alpha Rattus norvegicus 178-193 12504863-0 2003 Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Rotenone 13-21 synuclein alpha Rattus norvegicus 85-100 12504863-1 2003 Previous studies demonstrated that chronic systemic exposure to the pesticide and mitochondrial toxin rotenone through jugular vein cannulation reproduced many features of Parkinson"s disease (PD) in rats, including nigrostriatal dopaminergic degeneration and formation of alpha-synuclein-positive cytoplasmic inclusions in nigral neurons (R. Betarbet et al., 2000, Nat. Rotenone 102-110 synuclein alpha Rattus norvegicus 273-288 12504863-9 2003 Subcutaneous rotenone exposure caused alpha-synuclein-positive cytoplasmic aggregates in nigral neurons. Rotenone 13-21 synuclein alpha Rattus norvegicus 38-53 11100151-3 2000 Nigral neurons in rotenone-treated rats accumulate fibrillar cytoplasmic inclusions that contain ubiquitin and alpha-synuclein. Rotenone 18-26 synuclein alpha Rattus norvegicus 111-126 12177198-1 2002 Chronic systemic complex I inhibition caused by rotenone exposure induces features of Parkinson"s disease (PD) in rats, including selective nigrostriatal dopaminergic degeneration and formation of ubiquitin- and alpha-synuclein-positive inclusions (Betarbet et al., 2000). Rotenone 48-56 synuclein alpha Rattus norvegicus 212-227 34361780-14 2021 In addition to these mechanisms, noscapine prevented a rotenone-mediated increase in lysosomal degradation, resulting in a decrease in alpha-synuclein aggregation. Rotenone 55-63 synuclein alpha Rattus norvegicus 135-150 34896331-9 2022 NaB activated autophagy pathway and reduced rotenone-induced alpha-synuclein expression through the activation of autophagy. Rotenone 44-52 synuclein alpha Rattus norvegicus 61-76 34656609-11 2022 These results were correlated with reduction in alpha-synuclein immunoreactivity, together with improvement of Bax/Bcl2 ratio compared to rotenone group. Rotenone 138-146 synuclein alpha Rattus norvegicus 48-63 32905883-2 2020 We previously showed that alpha-Synuclein knockdown protected rat substantia nigra dopaminergic neurons from systemic exposure to the mitochondrial complex I inhibitor rotenone. Rotenone 168-176 synuclein alpha Rattus norvegicus 26-41 33578261-8 2021 halted PD motor impairment, prevented rotenone-induced weight loss, restored normal histological tissue structure, reversed rotenone-induced reduction in TH expression and striatal DA content, and markedly decreased midbrain and striatal alpha-synuclein expression in rotenone-treated rats. Rotenone 38-46 synuclein alpha Rattus norvegicus 238-253 33578261-8 2021 halted PD motor impairment, prevented rotenone-induced weight loss, restored normal histological tissue structure, reversed rotenone-induced reduction in TH expression and striatal DA content, and markedly decreased midbrain and striatal alpha-synuclein expression in rotenone-treated rats. Rotenone 124-132 synuclein alpha Rattus norvegicus 238-253 33578261-8 2021 halted PD motor impairment, prevented rotenone-induced weight loss, restored normal histological tissue structure, reversed rotenone-induced reduction in TH expression and striatal DA content, and markedly decreased midbrain and striatal alpha-synuclein expression in rotenone-treated rats. Rotenone 124-132 synuclein alpha Rattus norvegicus 238-253 33927622-5 2021 Cory was shown to exhibit neuroprotective effects in the two rotenone-induced models of PD by improving motor dysfunction, preventing tyrosine hydroxylase (TH)-positive neuronal loss, decreasing alpha-synuclein aggregates through the mechanistic target of the rapamycin (mTOR) pathway, and diminishing neuroinflammation. Rotenone 61-69 synuclein alpha Rattus norvegicus 195-210 33220427-9 2021 Chronic administration of rotenone caused PD-related pathological processes like oxidative stress, and produced a significant decrease in tyrosine hydroxylase (TH), DA transporter (DAT), Vesicular monoamine transporter 2 (VMAT2), and a significant upregulated in alpha-synuclein and apoptotic protein expression of Bax, Cyt-C and caspases -3, -8 and -9 as well as by decreasing Bcl2 expression. Rotenone 26-34 synuclein alpha Rattus norvegicus 263-278 33081327-8 2020 In our study, we found that Val prevented rotenone induced upregulation of pro-inflammatory cytokine oxidative stress, and alpha-synuclein expression with subsequent increase in vital antioxidant enzymes. Rotenone 42-50 synuclein alpha Rattus norvegicus 123-138 34558543-7 2022 After binding to the Mas receptor, angiotensin-(1-7) attenuated apoptosis and alpha-synuclein aggregation in rotenone-treated cells. Rotenone 109-117 synuclein alpha Rattus norvegicus 78-93 34558543-9 2022 Angiotensin-(1-7) increased alpha-synuclein removal and increased the autophagy of rotenone-treated cells. Rotenone 83-91 synuclein alpha Rattus norvegicus 28-43 31408200-6 2019 Treatment of rats with ABZ markedly mitigated rotenone-induced histological alterations in substantia nigra (SN), restored striatal dopamine (DA) level and motor functions and decreased the expression of alpha-synuclein (a disease marker protein). Rotenone 46-54 synuclein alpha Rattus norvegicus 204-219 31185705-5 2019 Further, rotenone administration activated microglia and astroglia, which in turn upregulated the expression of alpha-synuclein, pro-inflammatory, and oxidative stress factors, resulting in PD pathology. Rotenone 9-17 synuclein alpha Rattus norvegicus 112-127